These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 33177176)

  • 1. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma.
    Tripathi A; Lin E; Xie W; Flaifel A; Steinharter JA; Stern Gatof EN; Bouchard G; Fleischer JH; Martinez-Chanza N; Gray C; Mantia C; Thompson L; Wei XX; Giannakis M; McGregor BA; Choueiri TK; Agarwal N; McDermott DF; Signoretti S; Harshman LC
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
    Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
    Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ecto-5'-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells.
    Song L; Ye W; Cui Y; Lu J; Zhang Y; Ding N; Hu W; Pei H; Yue Z; Zhou G
    Oncotarget; 2017 May; 8(19):31977-31992. PubMed ID: 28404888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
    Buisseret L; Pommey S; Allard B; Garaud S; Bergeron M; Cousineau I; Ameye L; Bareche Y; Paesmans M; Crown JPA; Di Leo A; Loi S; Piccart-Gebhart M; Willard-Gallo K; Sotiriou C; Stagg J
    Ann Oncol; 2018 Apr; 29(4):1056-1062. PubMed ID: 29145561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.
    Labadie BW; Liu P; Bao R; Crist M; Fernandes R; Ferreira L; Graupner S; Poklepovic AS; Duran I; Maleki Vareki S; Balar AV; Luke JJ
    J Transl Med; 2019 Nov; 17(1):386. PubMed ID: 31767020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
    Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
    Front Immunol; 2021; 12():734646. PubMed ID: 34795663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of CD73/adenosine 2A receptor (A2AR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features.
    Takamatsu D; Kiyozawa D; Kohashi K; Kinoshita F; Toda Y; Ishihara S; Eto M; Oda Y
    Pathol Res Pract; 2023 Apr; 244():154423. PubMed ID: 36989848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor CD73/A2aR adenosine immunosuppressive axis and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma: correlations with clinicopathological characteristics and clinical outcome.
    Wang X; Zhang T; Song Z; Li L; Zhang X; Liu J; Liu X; Qiu L; Qian Z; Zhou S; Feng L; Hu G; Meng B; Zhai Q; Ren X; Fu K; Li L; Wang P; Zhang H
    Int J Cancer; 2019 Sep; 145(5):1414-1422. PubMed ID: 30664812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ENTPD1 (CD39) and NT5E (CD73) expression in human glioblastoma: an in silico analysis.
    Braganhol E; de Andrade GPB; Santos GT; Stefani MA
    Purinergic Signal; 2024 Jun; 20(3):285-289. PubMed ID: 37402102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detailed analysis of adenosine A2a receptor (
    Vogt TJ; Gevensleben H; Dietrich J; Kristiansen G; Bootz F; Landsberg J; Goltz D; Dietrich D
    Oncoimmunology; 2018; 7(8):e1452579. PubMed ID: 30221045
    [No Abstract]   [Full Text] [Related]  

  • 11. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
    Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
    Front Immunol; 2022; 13():975847. PubMed ID: 36091055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD73 as a potential opportunity for cancer immunotherapy.
    Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
    Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
    Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
    Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.
    Inoue Y; Yoshimura K; Kurabe N; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Oncotarget; 2017 Jan; 8(5):8738-8751. PubMed ID: 28060732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E.
    Kordaß T; Osen W; Eichmüller SB
    Front Immunol; 2018; 9():813. PubMed ID: 29720980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex regulation of ecto-5'-nucleotidase/CD73 and A
    Nedeljkovic N
    Pharmacol Res; 2019 Jun; 144():99-115. PubMed ID: 30954629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.
    Kamai T; Kijima T; Tsuzuki T; Nukui A; Abe H; Arai K; Yoshida KI
    Cancer Immunol Immunother; 2021 Jul; 70(7):2009-2021. PubMed ID: 33416945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioinformatics profiling integrating a four immune-related long non-coding RNAs signature as a prognostic model for papillary renal cell carcinoma.
    Liu Y; Gou X; Wei Z; Yu H; Zhou X; Li X
    Aging (Albany NY); 2020 Jul; 12(15):15359-15373. PubMed ID: 32716909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-Throughput Screening Assays for Cancer Immunotherapy Targets: Ectonucleotidases CD39 and CD73.
    Kumar M; Lowery R; Kumar V
    SLAS Discov; 2020 Mar; 25(3):320-326. PubMed ID: 31868071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.
    Chen Q; Pu N; Yin H; Zhang J; Zhao G; Lou W; Wu W
    J Cell Mol Med; 2020 Aug; 24(15):8674-8686. PubMed ID: 32643277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.